title: CCNU, vinblastine, and delalutin therapy in renal cell carcinoma.
abstract: Advanced renal cell carcinoma is relatively resistant to most adequately evaluated chemotherapeutic agents. The combination of CCNU and vinblastine, which has antitumor activity in a frog renal carcinoma model system, has demonstrated activity in initial studies in man. The current study investigated this combination of drugs together with a progestational agent, Delalutin. Seventeen patients with metastatic renal cell carcinoma were treated with CCNU, vinblastine and Delalutin. There were no objective responses. Four patients with stable disease had a mean survival of 18 months compared to 13 patients with progressive disease who had a mean survival of 5 months. The survival of the four patients with stable disease was in large part due to the slowly progressive natural history of their disease.
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008130:Lomustine / Q000008:administration & dosage*; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000008:administration & dosage*; D014747:Vinblastine / Q000008:administration & dosage*
chemical_list: D006908:Hydroxyprogesterones; D009607:Nitrosourea Compounds; D014747:Vinblastine; D008130:Lomustine